A Mathematical Model of Metformin Action on COVID-19 Risk Infection in Cardiovascular Diabetic Patients Studied by FTIR Spectroscopy.

Publication date: Jun 30, 2025

Several studies have revealed that patients with type 2 diabetes (T2D) infected with COVID-19 who were medicated with metformin showed higher recovery rates than those administered other antidiabetic drugs. To determine the mechanism of action of antidiabetic drugs against COVID-19, we developed a mathematical model that was based on the number of infected and recovered T2D patients. Moreover, the “diagnostic frequencies” of the infected T2D patients, determined using Fourier-Transform Infrared (FTIR) spectroscopy, were very helpful. In particular, the band at 1775 cm, attributed to IgG antibodies, could be used as a “diagnostic frequency” for COVID-19 infection. The increased intensity of the band of vC-O-C sugar moieties suggests an increased number of OH chemical groups that enhance the binding sites of SARS-CoV-2 spike protein for entering host cells. The changes were more pronounced in patients medicated with thiazolidinediones than those using insulin and metformin. Both FTIR spectra and the developed mathematical model confirmed that patients using thiazolidinediones showed a higher risk of COVID-19 infection and mortality. The data support the hypothesis that the NH chemical groups of metformin molecules interact directly through the SARS-CoV-2 spike protein, preventing the entry of COVID-19 into the host membrane cells. Indirectly, metformin inhibits the host binding sites for COVID-19 entry by lowering AGE production.

Open Access PDF

Concepts Keywords
Antibodies Cardiovascular Diseases
Diabetes COVID-19
Increased COVID-19
Mathematical COVID-19 Drug Treatment
Medicated diabetes
Diabetes Mellitus, Type 2
FTIR spectroscopy
Humans
Hypoglycemic Agents
Hypoglycemic Agents
infected and recovered
insulin
Male
mathematical model
Metformin
Metformin
metformin
Middle Aged
Models, Theoretical
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Thiazolidinediones
Thiazolidinediones
thiazolidinediones

Semantics

Type Source Name
drug DRUGBANK Metformin
disease MESH COVID-19
disease MESH Infection
disease MESH type 2 diabetes
drug DRUGBANK Albendazole
disease IDO host
disease IDO production
drug DRUGBANK Coenzyme M
disease IDO protein
disease MESH metabolic disease
drug DRUGBANK Dextrose unspecified form
disease MESH heart attack
disease MESH stroke
disease IDO pathogen
drug DRUGBANK Methionine
disease MESH morbidity
disease MESH inflammation
drug DRUGBANK Cardiolipin
disease MESH acidosis
disease MESH etiology
disease MESH oxidative stress
drug DRUGBANK 2 4-thiazolidinedione
disease MESH viral infection
drug DRUGBANK Cholesterol
disease IDO history
drug DRUGBANK Sodium lauryl sulfate
pathway REACTOME Protein folding
disease MESH diabetes complications
drug DRUGBANK Amino acids
drug DRUGBANK Nitrogen
disease MESH weight gain
disease MESH edema
disease MESH heart failure
disease IDO site
drug DRUGBANK L-Arginine
drug DRUGBANK L-Tyrosine
drug DRUGBANK Calcium cation
pathway REACTOME Release
drug DRUGBANK ATP
pathway REACTOME Reproduction
disease IDO algorithm
drug DRUGBANK Formaldehyde
disease MESH atherosclerosis
disease MESH diabetes mellitus
disease IDO facility
drug DRUGBANK Nonoxynol-9
disease MESH cancers
drug DRUGBANK Serine
drug DRUGBANK Stavudine
drug DRUGBANK Sulfasalazine
disease MESH Cardiovascular Diseases

Original Article

(Visited 6 times, 1 visits today)